The Project Is Focus On The Study Of Investigating New Anticancer Compounds From Marine Seaweed. Cancer Is Globally Recognized As One Of The Most Life-threatening Diseases And A Leading Cause Of Human Mortality. Specifically, The Key Enzyme Of The PI3K/AKTs/mTOR Signaling Pathway, Whose Overactivation Contributes To The Development Of Many Human Cancers And Resistance To Chemotherapeutic Drugs. The Marine Environment Represents A Unique Source Of Bioactive Compounds With High Pharmaceutical Potential. Seaweeds, Rich In Bioactive Compounds, Have Gained Attention For Their Therapeutic Potential. The Main Emphasis Has Been Given To Evaluating Certain Metabolites From The Seaweed With Sensitive Protein Molecules Of Oral, Liver, Lung, Ovarian, Pancreatic, And Breast Cancer, Using In Silico Approaches. The Compounds 8-Hydroxy-3-chlorodibenzofuran, Aplysin, Miraxanthin-I, Fexofenadine, 8,8a-Deoxyoleandolide, Somniferine, Carbenicillin, And Milbemectin Indicate Good Binding Affinity With Oral Cancer Protein When Compared With The Synthetic Drug Hydroxyurea And 5-fluorouracil (5-FU). Further Other Seaweed Compounds Will Be Screened Against The Different Types Of Cancer And Tested For Pharmacokinetic Properties (under Process). These Compounds May Act As Potential Leads For Identifying A New Cancer Drug.